Jade Biosciences, Inc. Common Stock (JBIO) Stock
NASDAQ · JBIO
14.25
Fundamentals
Market cap
$917.07M
Price / Earnings ratio
-6.1x
Price / Sales ratio
N/A
Price / Book ratio
2.1x
Return on assets
-47.0%
Ex-Dividend date
29 Apr 2025
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
420M277M139M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-127.4M
Net incomeEarnings
No data available
% positive news of 1 articles
published over the past 14 days
About Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
SectorHealthcare
IndustryBiotechnology
Employees55
CEOMr. Tom Frohlich
IPO DateJun 30, 2021
HeadquartersWaltham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Tom Frohlich | President, CEO & Director | 1976 |
| Mr. Bradford D. Dahms Ph.D. | CFO & Treasurer | 1989 |
| Dr. Andrew James King BVMS, D.V.M., Ph.D. | President of Research & Development | 1980 |
| Ms. Elizabeth Balta J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Ms. Lori Stewart | Senior Vice President of People | — |
| Mr. Jonathan Quick | Senior Vice President of Finance | — |
| Ms. Valerie Fauvelle | Senior Vice President of Regulatory & Quality | — |
| Ms. Amy Sullivan | Senior Vice President of Development Operations | — |
| Ms. Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | — |
| Dr. Edward R. Conner M.D. | Chief Medical Officer | 1973 |
Fundamentals
Valuation
Market cap$917.07M
Price-to-sales ratioN/A
Price-to-book value2.13
Price-earnings ratio-6.10
Return on Equity-51.00%
Return on SalesN/A
Return on Assets-47.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.92
Income Statement
Average volume962,286
EBITDA$-129.40M
1 year high (52w)$28.00
1 year low (52w)$7.69
Dividend
Ex dividend date29 Apr 2025
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$62.00
Est return
321.77%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.6 | +52.3 | -13.2 | +19.5 | -9.4 | +11.5 | -31.4 |




